ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Cara Therapeutics Submits NDA for KORSUVA Injection
December 31, 2020Cara Therapeutics has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for KORSUVA™ Injection (difelikefalin) for the treatment of moderate-to-severe pruritus in hemodialysis patients. -
Cara Therapeutics Initiates Second Pruritus Phase 2 Trial of Peptelligence®
June 28, 2019Enteris BioPharma congratulates Cara Therapeutics on the successful initiation of its Phase 2 clinical trial of Oral KORSUVA™ (CR845/difelikefalin) for the treatment of pruritus in patients with hepatic impairment due to primary biliary cholangitis (PBC). -
Cara Therapeutics Announces Proposed Offering of Common Stock
March 30, 2017Cara Therapeutics, Inc. (CARA)announced that it has commenced an underwritten public offering of $80 million of shares of its common stock.
Pharma Sources Insight January 2025
